

ABSTRACT

A problem to be solved by the present invention is to provide a new drug for preventing, suppressing the progression of symptoms of or the recurrence of or treating autoimmune diseases. The inventors of the present invention have diligently studied, and focused on the PD-1/CD3 bispecific antibody as a substance to dissolve such a problem. Furthermore, the inventors have confirmed that the substance could be a formulation which can reduce the occurrence of adverse reactions called as infusion reaction or cytokine release syndrome. They confirmed that the bispecific antibody has the feature to allow the interaction between PD-1 and PD-L1 as its ligand, and found that such a feature contributes enhancement or duration of effect of preventing, suppressing the progression of symptoms of or the recurrence of or treating autoimmune diseases.